MDR-001
A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight
MindRank AI Ltd · Phase 2 · Status n/r · Enrollment 300
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 90 mg MDR-001 | n/r | n/r | n/r | n/r |
| 120 mg MDR-001 | n/r | n/r | n/r | n/r |
| 150 mg MDR-001 | n/r | n/r | n/r | n/r |
| 180 mg MDR-001 | n/r | n/r | n/r | n/r |
| placebo | n/r | n/r | n/r | n/r |
Not shown
- 90 mg MDR-001: endpoint not reported
- 120 mg MDR-001: endpoint not reported
- 150 mg MDR-001: endpoint not reported
- 180 mg MDR-001: endpoint not reported
- placebo: endpoint not reported